These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 20031711

  • 1. Unprotected left main intervention: the light at the end of the tunnel?
    Stone GW, Mintz GS.
    Circ Cardiovasc Interv; 2009 Jun; 2(3):156-8. PubMed ID: 20031711
    [No Abstract] [Full Text] [Related]

  • 2. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis.
    Park SJ, Kim YH, Park DW, Lee SW, Kim WJ, Suh J, Yun SC, Lee CW, Hong MK, Lee JH, Park SW, MAIN-COMPARE Investigators.
    Circ Cardiovasc Interv; 2009 Jun; 2(3):167-77. PubMed ID: 20031713
    [Abstract] [Full Text] [Related]

  • 3. A critical appraisal of the Janus carbostent.
    Kornowski R.
    Catheter Cardiovasc Interv; 2009 Feb 01; 73(2):249-50. PubMed ID: 19156897
    [No Abstract] [Full Text] [Related]

  • 4. Better results with the new generation bare metal stents.
    Vik-Mo H.
    Scand Cardiovasc J; 2009 Apr 01; 43(2):84-6. PubMed ID: 19117238
    [No Abstract] [Full Text] [Related]

  • 5. Prediction of outcomes after percutaneous coronary intervention for unprotected left main coronary artery stenosis using the EuroSCORE.
    Park SJ.
    Catheter Cardiovasc Interv; 2011 Apr 01; 77(5):633. PubMed ID: 21433266
    [No Abstract] [Full Text] [Related]

  • 6. High glycemic stenting menu.
    Hillegass WB.
    Catheter Cardiovasc Interv; 2010 Dec 01; 76(7):934-5. PubMed ID: 21108370
    [No Abstract] [Full Text] [Related]

  • 7. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M, Serruys PW, Miquel-Hebert K, Neumann FJ, Piek JJ, Grube E, Haase J, Thuesen L, Hamm C.
    Catheter Cardiovasc Interv; 2010 Jun 01; 75(7):997-1003. PubMed ID: 20517959
    [Abstract] [Full Text] [Related]

  • 8. Angiographic restenosis and clinical recurrence after sirolimus- and paclitaxel-eluting stent implantation.
    Vlaar PJ, Zijlstra F.
    JACC Cardiovasc Interv; 2009 Aug 01; 2(8):776-8. PubMed ID: 19695547
    [No Abstract] [Full Text] [Related]

  • 9. If you want to stent ... do intravascular ultrasound!
    Hodgson JM.
    JACC Cardiovasc Interv; 2010 Aug 01; 3(8):818-20. PubMed ID: 20723853
    [No Abstract] [Full Text] [Related]

  • 10. The continuing diabetic drug-eluting stents saga from very-late stent thrombosis to very-late late loss.
    Mak KH.
    JACC Cardiovasc Interv; 2011 Mar 01; 4(3):324-6. PubMed ID: 21435611
    [No Abstract] [Full Text] [Related]

  • 11. Native vessel PCI in the diabetic: DES whenever feasible.
    Hillegass W.
    Catheter Cardiovasc Interv; 2008 Nov 01; 72(5):608-9. PubMed ID: 18949773
    [No Abstract] [Full Text] [Related]

  • 12. Early and long-term results of percutaneous coronary intervention for unprotected left main trifurcation disease.
    Sheiban I, Gerasimou A, Bollati M, Biondi-Zoccai G, Sciuto F, Omedé P, Sillano D, Trevi GP, Moretti C.
    Catheter Cardiovasc Interv; 2009 Jan 01; 73(1):25-31. PubMed ID: 19089932
    [Abstract] [Full Text] [Related]

  • 13. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V, Cutlip D, Kleiman N, Pencina M, Mauri L, Yen CH, Berger P, Goldberg S, Kellett M, Waksman R, Hong M, Raizner AE, Cohen DJ.
    JACC Cardiovasc Interv; 2009 Aug 01; 2(8):767-75. PubMed ID: 19695546
    [Abstract] [Full Text] [Related]

  • 14. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS, Ribeiro EE, Martinez EE, PAINT trial investigators.
    Catheter Cardiovasc Interv; 2009 Nov 01; 74(5):665-73. PubMed ID: 19670303
    [Abstract] [Full Text] [Related]

  • 15. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
    Simard T, Hibbert B, Chong AY, Ruchin P, Le May M, Labinaz M, Froeschl M, So D, Glover C, Marquis JF, O'Brien E.
    Catheter Cardiovasc Interv; 2012 Aug 01; 80(2):E15-22. PubMed ID: 21805580
    [Abstract] [Full Text] [Related]

  • 16. A generation 2.5 drug-eluting stent?
    Ellis SG.
    JACC Cardiovasc Interv; 2009 Oct 01; 2(10):986-8. PubMed ID: 19850259
    [No Abstract] [Full Text] [Related]

  • 17. Sirolimus- versus paclitaxel-eluting stents for unselected patients with coronary artery disease.
    Park SJ.
    Catheter Cardiovasc Interv; 2011 Jan 01; 77(1):13-4. PubMed ID: 21181967
    [No Abstract] [Full Text] [Related]

  • 18. Percutaneous left main invention an evolving perspective.
    Ellis SG.
    JACC Cardiovasc Interv; 2010 Jun 01; 3(6):642-7. PubMed ID: 20630457
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of single- versus two-stent techniques in treatment of unprotected left main coronary bifurcation disease.
    Kim WJ, Kim YH, Park DW, Yun SC, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ.
    Catheter Cardiovasc Interv; 2011 May 01; 77(6):775-82. PubMed ID: 21520380
    [Abstract] [Full Text] [Related]

  • 20. We can build it, but will they come?
    Gilchrist IC.
    Catheter Cardiovasc Interv; 2011 May 01; 77(6):818-9. PubMed ID: 21520383
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.